{"classes":[{"categories":[{"measurements":[{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"0.9","upperLimit":"NA","value":"1.4"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"1.4","upperLimit":"NA","value":"4.0"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"1.2","upperLimit":"NA","value":"2.3"},{"groupId":"OG003","lowerLimit":"1.1","upperLimit":"3.2","value":"1.5"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG004","lowerLimit":"1.2","upperLimit":"NA","value":"1.3"},{"groupId":"OG005","lowerLimit":"4.6","upperLimit":"13.3","value":"6.7"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG006","lowerLimit":"9.8","upperLimit":"NA","value":"14.6"},{"comment":"TTP median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG007","lowerLimit":"4.5","upperLimit":"NA","value":"NA"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG008","lowerLimit":"3.2","upperLimit":"NA","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"6"}],"units":"Participants"}],"description":"Time from first dose of study drug to the first documentation of progressive disease (PD). Participants were considered to have progressive disease if they had documented progression based on radiologic assessment according to RECIST v1.1. RECIST v1.1 defined disease progression as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose escalation with rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG000","title":"Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG001","title":"Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.","id":"OG002","title":"Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6"},{"description":"Dose expansion in TNBC participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG003","title":"Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG004","title":"Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG005","title":"Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG006","title":"Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG007","title":"Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG008","title":"Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5"}],"paramType":"MEDIAN","populationDescription":"mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"First Dose of Study Drug to PD (Up to 1.63 years)","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}